Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2019 Feb 19;9(1):2250.
doi: 10.1038/s41598-019-38759-5.

Impact of gynecologic cancer on pelvic floor disorder symptoms and quality of life: an observational study

Mathias Neron  1 , Sophie Bastide  2 , Renaud de Tayrac  3 , Florent Masia  3 , Catherine Ferrer  3 , Majd Labaki  3 , Laurent Boileau  3 , Vincent Letouzey  3 , Stephanie Huberlant  3
Affiliations
Observational Study

Impact of gynecologic cancer on pelvic floor disorder symptoms and quality of life: an observational study

Mathias Neron et al. Sci Rep. .

Abstract

The objective of our observational prospective study was to investigate the severity and prevalence of urinary and pelvic floor disorders in gynecologic cancer survivors. All patients surviving gynecological cancer in the region as well as women receiving invitations to attend breast-screening checkups as the control population were asked to fill-in questionnaires assessing pelvic prolapse symptoms (PFDI-20, Wexner) and associated quality of life (PFIQ-7). Eighty-nine women were included in the cancer survivor group and 1088 in the control group. Pelvic floor symptoms (PFDI-20 questionnaire) were significantly worse in cancer survivors than in control women (score: 33.3 [14.6-74.1] vs. 20 [4.2-50.0], p = 0.0003). Urge incontinence was significantly worse in cancer survivors in both univariable (ORb = 2.061 [95% CI = 1.284-3.309], p = 0.0027) and multivariable analyses (ORa = 1.672 [95% CI = 1.014-2.758], p = 0.0442), as was fecal incontinence in univariable (ORb = 3.836 [95% CI = 1.710-8.602], p = 0.0011) and in multivariable (ORa = 3.862 [95% CI = 1.657-9.001], p = 0.0018) analyses. Women with benign hysterectomies had poorer quality of life and increased pelvic floor disorders compared to women with no history of surgery. Survivors of gynecological cancer experience significantly more pelvic floor symptoms and an associated reduction in quality of life.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Figure 1
Figure 1
Flow chart.
Figure 2
Figure 2
Boxplot comparing PFDI-20 global score of (A) cancer survivor (CS) to control group (CG) and (B) cancer survivors (CS) to women who underwent benign hysterectomy (CGH+) and women with no history of cancer or hysterectomy (CGH−). Global score ranges from 0 to 300, higher scores represent more symptoms and associated discomfort.
Figure 3
Figure 3
Boxplot comparing PFIQ-7 global score of (A) cancer survivor (CS) to control group (CG) and (B) cancer survivors (CS) to women who underwent benign hysterectomy (CGH+) and women with no history of cancer or hysterectomy (CGH−). Global score ranges from 0 to 300, higher scores represent a stronger impact of symptoms on quality of life.
See this image and copyright information in PMC

References

    1. Ferlay J, et al. Cancer incidence and mortality patterns inEurope: estimates for 40 countries in 2012. Eur. J. Cancer Oxf. Engl. 1990. 2013;49:1374–1403. - PubMed
    1. Council, I. of M. and N. R. From Cancer Patient to Cancer Survivor: Lost in Transition, 10.17226/11468 (2005).
    1. Cancer Survivorship - United States, 1971–2001. Available at, https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5324a3.htm (Accessed: 19th November 2017).
    1. us_cancer_statistics_2004_incidence_and_mortality.pdf. Available at, https://www.cdc.gov/cancer/npcr/npcrpdfs/us_cancer_statistics_2004_incid... (Accessed: 19th November 2017).
    1. Bosetti C, et al. Cancer mortality in Europe, 2005-2009, and an overview of trends since 1980. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2013;24:2657–2671. doi: 10.1093/annonc/mdt301. - DOI - PubMed

Publication types